Merck (MRK) EBT Margin (2009 - 2026)
Merck (MRK) reported EBT Margin of 21.49% for Q1 2026, down 5950.0% year-over-year from 0.37% in Q1 2025, and down 203.06% on a QoQ basis from 20.85% in Q4 2025.
Merck (MRK) has 18 years of EBT Margin data on file, last reported at 21.49% in Q1 2026.
- Quarterly EBT Margin fell 5950.0% year-over-year to 21.49% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 17.74% (down 1382.0% YoY) and the FY2025 annual result came in at 32.41%, up 134.0% from the prior year.
- EBT Margin slipped to 21.49% in Q1 2026 per MRK's latest filing, from 20.85% in the prior quarter.
- Across five years, EBT Margin topped out at 39.04% in Q3 2025 and bottomed at 35.25% in Q2 2023.
- The 5-year median for EBT Margin is 26.69% (2024), against an average of 20.84%.
- The widest annual swing landed in 2023, when EBT Margin sank 6600 bps; it then surged 7253 bps in 2024.
- Tracing MRK's EBT Margin over 5 years: stood at 25.4% in 2022, then sank by 155 bps to 13.98% in 2023, then surged by 291 bps to 26.69% in 2024, then fell by 22 bps to 20.85% in 2025, then tumbled by 203 bps to 21.49% in 2026.
- Per Business Quant, the three latest MRK EBT Margin figures stand at 21.49% (Q1 2026), 20.85% (Q4 2025), and 39.04% (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Novartis Ag | 107,124,802.25 Bn | 107,124,802.25 Bn | - | - |
| 2 | Eli Lilly | 969.00 Bn | 963.72 Bn | 16.22 Bn | 44.70% |
| 3 | Johnson & Johnson | 539.46 Bn | 517.41 Bn | 15.96 Bn | 24.89% |
| 4 | AbbVie | 376.92 Bn | 367.57 Bn | 10.78 Bn | 6.93% |
| 5 | Merck | 285.00 Bn | 279.35 Bn | 12.09 Bn | -21.49% |
| 6 | Amgen | 177.58 Bn | 165.55 Bn | 5.87 Bn | 24.18% |
| 7 | Gilead Sciences | 163.22 Bn | 155.50 Bn | 5.52 Bn | 37.07% |
| 8 | Pfizer | 145.86 Bn | 133.09 Bn | -1.21 Bn | 135.53% |
| 9 | Bristol Myers Squibb | 111.90 Bn | 101.44 Bn | 8.07 Bn | 28.20% |
| 10 | Gsk | 88.34 Bn | 83.66 Bn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -21.49% |
| Dec 31, 2025 | 20.85% |
| Sep 30, 2025 | 39.04% |
| Jun 30, 2025 | 31.63% |
| Mar 31, 2025 | 38.01% |
| Dec 31, 2024 | 26.69% |
| Sep 30, 2024 | 24.55% |
| Jun 30, 2024 | 37.28% |
| Mar 31, 2024 | 35.94% |
| Dec 31, 2023 | -13.98% |
| Sep 30, 2023 | 35.21% |
| Jun 30, 2023 | -35.25% |
| Mar 31, 2023 | 25.20% |
| Dec 31, 2022 | 25.40% |
| Sep 30, 2022 | 23.95% |
| Jun 30, 2022 | 30.75% |
| Mar 31, 2022 | 30.57% |
| Dec 31, 2021 | 28.91% |
| Sep 30, 2021 | 40.03% |
| Jun 30, 2021 | 15.06% |
| Mar 31, 2021 | 28.11% |
| Dec 31, 2020 | -23.25% |
| Sep 30, 2020 | 24.76% |
| Jun 30, 2020 | 29.31% |
| Mar 31, 2020 | 31.83% |
| Dec 31, 2019 | -36.20% |
| Sep 30, 2019 | 18.93% |
| Jun 30, 2019 | 27.71% |
| Mar 31, 2019 | 28.36% |
| Dec 31, 2018 | 23.68% |
| Sep 30, 2018 | 24.69% |
| Jun 30, 2018 | 19.93% |
| Mar 31, 2018 | 13.40% |
| Dec 31, 2017 | 18.01% |
| Sep 30, 2017 | 1.94% |
| Jun 30, 2017 | 24.56% |
| Mar 31, 2017 | 21.23% |
| Dec 31, 2016 | -13.41% |
| Sep 30, 2016 | 27.40% |
| Jun 30, 2016 | 15.28% |
| Mar 31, 2016 | 17.44% |
| Dec 31, 2015 | 7.99% |
| Sep 30, 2015 | 23.80% |
| Jun 30, 2015 | 8.25% |
| Mar 31, 2015 | 14.65% |
| Dec 31, 2014 | 112.68% |
| Sep 30, 2014 | 14.11% |
| Jun 30, 2014 | 17.29% |
| Mar 31, 2014 | 20.37% |
| Dec 31, 2013 | 10.82% |
| Sep 30, 2013 | 13.82% |
| Jun 30, 2013 | 11.31% |
| Mar 31, 2013 | 14.53% |
| Dec 31, 2012 | 11.37% |
| Sep 30, 2012 | 19.31% |
| Jun 30, 2012 | 21.77% |
| Mar 31, 2012 | 21.37% |
| Dec 31, 2011 | 12.86% |
| Sep 30, 2011 | 19.56% |
| Jun 30, 2011 | 13.76% |
| Mar 31, 2011 | 14.93% |
| Dec 31, 2010 | -15.34% |
| Sep 30, 2010 | 4.48% |
| Jun 30, 2010 | 10.94% |
| Mar 31, 2010 | 5.65% |
| Dec 31, 2009 | 128.51% |
| Sep 30, 2009 | 10.12% |
| Jun 30, 2009 | 13.10% |
| Mar 31, 2009 | 20.98% |